Zu den Inhalten springen

Tumorzentrum Freiburg - CCCF

Prof. Dr. med. Dr. nat. med. Philipp Tobias Meyer


Department of Nuclear Medicine
University Hospital Freiburg
Hugstetter Str. 55
D - 79106 Freiburg
Phone +49 (0)761-270.39160

Current Positions:

Director, Department of Nuclear Medicine, University Hospital Freiburg

Research Focus:

  • Peptide-receptor-based theranostics (molecular imaging and therapy) of malignant tumors
  • Biological imaging for radiation treatment planning
  • Hybrid imaging with SPECT/CT and PET/CT
  • Quantification and analysis methods for PET and SPECT
  • Preclinical small animal imaging (also CRC 850 Project)
  • Molecular neuroimaging in neurodegenerative diseases

Clinical Focus:

  • Imaging with PET and SPECT for tumor diagnosis, staging, therapy control and follow-up (e.g., in lymphoma, melanoma, lung, breast and colorectal cancer, neuroendocrine and brain tumors)
  • Peptide-receptor-based diagnostic imaging and radionuclide therapy (theranostics, e.g., in neuroendocrine tumors, prostate and breast cancer)
  • other radionuclide therapies (e.g., SIRT in liver tumors, Ra-223 therapy in prostate cancer, radioiodine therapy in benign and malignant thyroid diseases)
  • Molecular neuroimaging in neurodegenerative diseases, epilepsy and cerebrovascular disease
  • general nuclear medicine

DKTK Research Topics

Topic: Novel Imaging Biomarkers

  • Molecular probes for PET imaging and radionuclide therapy

Working Group Members DKTK:

Friederike Braun    Biologist, preclinical imaging
Dr. Eleni Gourni    Chemist, radiopharmacy
Prof. Dr. rer. nat. Helmut Mäcke    Chemist, radiopharmacy
Dr. rer. nat. Michael Mix    Physicist, imaging & dosimetry
Luigi del Pozzo    Chemist, radiopharmacy
PD Dr. med. Juri Ruf    Physician, clinical research
Christian Stoykow    Physician, preclinical and clinical research
Dr. med. Gesche Wieser    Physician, clinical research



Selected Publications*:

Yaktapour N, Meiss F, Mastroianni J, Zenz T, Andrlova H, Mathew NR, Claus R, Hutter B, Fröhling S, Brors B, Pfeifer D, Pantic M, Bartsch I, Spehl TS, Meyer PT, Duyster J, Zirlik K, Brummer T, Zeiser R. BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia. J Clin Invest. 2014 Nov 3;124(11):5074-84.

Niethammer M, Tang CC, Feigin A, Allen PJ, Heinen L, Hellwig S, Amtage F, Hanspal E, Vonsattel JP, Poston KL, Meyer PT, Leenders KL, Eidelberg D. A disease-specific metabolic brain network associated with corticobasal degeneration. Brain. 2014 Nov;137(Pt 11):3036-46.

Rischke HC, Beck T, Vach W, Wieser G, Grosu AL, Schultze-Seemann W, Meyer PT, Jilg CA. Furosemide diminishes ¹⁸F-fluoroethylcholine uptake in prostate cancer in vivo. Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2074-82.

Wieser G, Mansi R, Grosu AL, Schultze-Seemann W, Dumont-Walter RA, Meyer PT, Maecke HR, Reubi JC, Weber WA. Positron emission tomography (PET) imaging of prostate cancer with a gastrin releasing peptide receptor antagonist--from mice to men. Theranostics. 2014 Feb 1;4(4):412-9.

Hellwig S, Kreft A, Amtage F, Tüscher O, Winz OH, Hellwig B, Weiller C, Weber WA, Vach W, Meyer PT. 123I-iodobenzamide SPECT is not an independent predictor of dopaminergic responsiveness in patients with suspected atypical parkinsonian syndromes. J Nucl Med. 2013 Dec;54(12):2081-6.

Frings L, Spehl TS, Weber WA, Hüll M, Meyer PT. Amyloid-β load predicts medial temporal lobe dysfunction in Alzheimer dementia. J Nucl Med. 2013 Nov;54(11):1909-14.

Lohrmann C, Hauschild O, Meyer PT, Mix M, Strohm PC, Weber WA, Rischke HC. Hybrid imaging of peripheral skeletal disease by SPECT/high-resolution flat-panel CT. J Nucl Med. 2013 Aug;54(8):1323-6.

Kasenda B, Haug V, Schorb E, Fritsch K, Finke J, Mix M, Hader C, Weber WA, Illerhaus G, Meyer PT. 18F-FDG PET is an independent outcome predictor in primary central nervous system lymphoma. J Nucl Med. 2013 Feb;54(2):184-91.

Hellwig S, Amtage F, Kreft A, Buchert R, Winz OH, Vach W, Spehl TS, Rijntjes M, Hellwig B, Weiller C, Winkler C, Weber WA, Tüscher O, Meyer PT. [¹⁸F]FDG-PET is superior to [¹²³I]IBZM-SPECT for the differential diagnosis of parkinsonism. Neurology. 2012 Sep 25;79(13):1314-22.

*from 2012 - 2014

Site Coordinator Freiburg

Prof.Dr. Christoph Peters
Tumorzentrum Freiburg CCCF
Phone: +49-761-270-71500
Hugstetter Str. 55
79106 Freiburg


Institute of Molecular Medicine and Cell Research
University of Freiburg
Stefan-Meier-Str. 17
79104 Freiburg
Phone: +49-761-203-9600/9601

Administrative Site Coordination

Dr. Anja Hernández
Deutsches Krebsforschungszentrum (DKFZ)
Im Neuheimer Feld 280
69120 Heidelberg
+49 (0)761 270 22810